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1. Introduction 
 
Heart failure (HF) is a leading cause of morbidity and mortality worldwide and has a 
relevant impact on socio-economic health aspects (1). It can be defined as an abnormality of 
cardiac structure or function leading to failure of the heart to deliver blood, and so oxygen, at 
a rate adequate with tissues’ necessities, despite normal filling pressures or only at the 
expense of increased filling pressures (2). In addition, it can be clinically defined as a 
syndrome in which patients present typical symptoms (e.g. breathlessness, orthopnea, fatigue) 
and signs (e.g. elevated jugular venous pressure, pulmonary crackles, third heart sound) 
resulting from an abnormality of cardiac structure or function (2).  
In developed countries, 1-2% of the adult population is affected by HF and the 
prevalence follows an exponential pattern rising rates ≥10% among persons aged 70 years or 
older (1). In the classification of the international cardiology societies (European Society of 
Cardiology, American Heart Asociation) two prevalent forms of HF have been identified: HF 
with reduced left ventricular (LV) ejection fraction (HF-REF) and HF with preserved LV 
ejection fraction (HF-PEF). The former is most common and can be characterized by different 
degrees of LV systolic dysfunction. Moreover, it is mainly related to the presence of coronary 
artery disease, however other aetiologies may be identified, as viral myocardial infections, 
alcohol or drugs abuse, chemotherapy, hereditary myocardial proteins’ genes defects and 
idiopathic dilated cardiomyopathy (2).  
An insufficient cardiac function leads to the activation of several compensatory 
mechanism that simultaneously act in order to compensate the effects of a failing heart. These 
mechanisms mainly consist in neuro-hormonal activation, enhanced sympathetic nervous 
system activity and natriuretic peptides synthesis and release (3). All these mechanisms, 
whereas initially positively contribute to compensate peripheral effects of an impaired cardiac 
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function, on long-term become dangerous and activate a vicious circle in which “HF begets 
HF”. 
 
1.1 Sympathetic nervous system activity in heart failure: significance and prognostic 
implications of I123-labelled meta-iodobenzylguanidine (I123MIBG) Imaging  
As previously stated, HF is characterized by an increased activity of sympathetic 
nervous system that acts as a compensatory mechanism in the initial phase of the disease, but 
contributes to deleterious adverse effects in the long-term due to increased oxygen demand 
and myocardial work. The ‘hyperadrenergic state’ results in decreased responsiveness to b-
adrenergic receptor agonists, mainly caused by a reduced number (downregulation) and 
functional impairment (uncoupling) of receptors. In addition, prolonged sympathetic 
hyperactivity leads to direct detrimental cardiovascular effects, including excitation-
contraction coupling abnormalities and promotion of cell apoptosis, which significantly 
contribute to HF progression (4). 
Imaging with MIBG, an analogue of norepinephrine (NE), depicts the status of cardiac 
innervation in patients with HF (5) and has been shown to yield prognostic information, with 
the potential to stratify patients for fatal and non-fatal cardiac events more accurately than 
traditional risk markers. In patients with HF, human NE transporter 1 activity is 
downregulated with an increase in NE cardiac spillover in the synaptic space and reduced NE 
concentration in the presynaptic nerve endings, resulting in reduced cardiac MIBG uptake and 
accelerated washout rate (WR) in patients with HF (4). I123MIBG is the result of an iodinated 
chemical modification of guanethidine with a molecular structure similar to NE, sharing the 
same uptake, storage and release processes. However, unlike NE, I123MIBG is not 
metabolized by monoamine oxidase or catechol-O-methyltransferase and it has no interaction 
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with the postsynaptic receptors. As a result, scintigraphic images obtained by labelling MIBG 
with 123I depict the status of catecholamine storage at the level of the myocardial sympathetic 
presynaptic fibers (6). To evaluate neuronal activity, I123MIBG uptake is semiquantified 
by calculating a heart to mediastinum ratio (H/M) after tracing regions of interest over the 
heart and the mediastinum. Neuronal integrity is also assessed by the I123MIBG WR, 
calculated by comparing early and late images (Figure 1). SPECT images are then analysed in 
conventional orthogonal planes (short axis, vertical and horizontal long axes). In patients with 
HF, reduced NE re-uptake in presynaptic neurons results in low MIBG cardiac uptake, while 
accelerated release kinetics leads to an increased WR (6). Cardiac neuronal abnormalities 
have been linked to the occurrence of several adverse events in patients affected by HF, as 
fatal ventricular arrhythmias, HF progression and overall mortality, included death for 
cardiovascular causes (7-9). Boogers et al. (10) reported data from a cohort of 116 patients 
with HF (mean EF 28%) who underwent MIBG imaging before ICD implantation and were 
followed for the occurrence of appropriate ICD therapy and cardiac death. In this study, the 
late MIBG SPECT defect score resulted in an independent predictor of appropriate ICD 
therapy and of cardiac death. Moreover, Tamaki et al. showed that, in 106 patients with LVEF 
<40%, those with sudden cardiac death had a significantly lower H/M and higher WR (8). At 
multivariate analysis only WR and EF were independent predictors of sudden cardiac death. 
Notably, WR showed higher specificity and predictive accuracy than EF and maintained its 
predictive capacity in patients with EF >35%, suggesting a role for I123MIBG to identify ICD 
candidates not currently included in guideline indications. The large multicenter AdreView 
Myocardial Imaging for Risk Evaluation in Heart Failure trial (ADMIRE-HF) (9) provided 
relevant confirmatory evidence for the independent prognostic role of I123MIBG in patients 
with HF. In this study, 961 patients with NYHA functional class I-III and EF ≤35%, while on 
optimised medical therapy, underwent cardiac I123MIBG imaging and myocardial perfusion 
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imaging and were followed for a mean of 17 months. A significantly lower risk (15%) of the 
composite end-point was observed in patients with late H/M ≥1.60 compared with those with 
H/M <1.60 (38%; HR 0.40, p<0.001), with a highly significant HR for each individual 
component of the composite primary end-point. Notably, 2-year all-cause mortality was more 
than fivefold higher in patients with H/M <1.60 than in those with H/M ≥1.60 (16.1% vs 3%). 
The multivariate and interaction analysis provided relevant information about the incremental 
prognostic value of I123MIBG above and beyond traditional risk markers. In particular, in the 
ADMIRE-HF population, multivariate analysis identified four independent predictors of the 
primary end-point (NYHA class, plasma levels of B-type natriuretic peptide, EF and late 
H/M) and, interestingly, plasma NE levels measured in the trial did not significantly 
contribute to the prognostic model, suggesting that cardiac direct assessment of neuronal 
activity by I123MIBG may be more useful than systemic evaluation reflected by NE plasma 
levels.  
 Thus, assessment of cardiac sympathetic activity by MIBG imaging represents a useful 
tool to depict the occurrence of increased sympathetic hyperactivity in HF and to follow its 
deleterious effects on disease progression. For clinical applications, MIBG imaging identifies, 
in addition to conventional functional and biohumoral parameters, patients at low or high risk 
of cardiac events and is able to track innervation changes induced by treatments. 
 
1.2 Aims and background of the research project 
 Aim of the present research path was to evaluate sympathetic nervous system at 
myocardial level in different settings of patients affected by HF-REF by the use of I123MIBG 
cardiac scintigraphic study. In particular, in the current report we present the results of cardiac 
sympathetic activity evaluation in 3 specific groups of HF-REF patients, as diabetic HF 
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patients, non-diabetic HF patients affected by insulin resistance (IR) and HF-REF patients 
also affected by sleep-disordered breathing (SDB). 
In the first study, we assessed myocardial adrenergic innervation in HF patients with 
severely reduced systolic function also affected by diabetes mellitus (DM), comparing this 
group to HF non-diabetic patients and to diabetic patients with normal cardiac structure and 
function. Aim of this analysis was to investigate if diabetes is associated with a further 
impairment of sympathetic activity and if parameters related to glycemic control may predict 
modifications of I123MIBG parameters, so of myocardial adrenergic activity. A strict 
relationship exists between diabetes and HF. DM is considered either cause or consequence of 
reduced cardiac function and adversely affects disease progression and occurrence of serious 
adverse events. Nevertheless, at the moment, few clinical data are available on the impact of 
DM on cardiac sympathetic activity in patients affected by HF, despite this relationship could 
be one of the mechanisms responsible for the negative impact of diabetes on HF evolution. 
This assumption suggests a potential working hypothesis for future mechanistic studies aimed 
at assessing whether glycation directly affects the process of cardiac sympathetic impairment. 
In the second phase of the research project we excluded diabetic patients and 
concentrated on non-diabetic HF patients also affected by IR. IR is quite common in HF also 
in absence of DM and can be considered as cause and/or consequence of HF and it has been 
associated with adverse prognosis. A close interaction exists between IR and sympathetic 
nervous system and this association may represent one of the pathophysiological mechanisms 
of adverse prognosis in HF patients also affected by IR. Thus, in this second study we tested 
the hypothesis that IR is associated with more impaired cardiac sympathetic innervation in 
non diabetic HF patients compared to those with HF but not IR, trying to explain a 
detrimental prognostic role of IR.  
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Finally, our last research aims to clarify the relationship between cardiac sympathetic 
innervation and SDB in HF patients. The interest for this field comes from the high 
prevalence and prognostic relevance of sleep apnea in systolic HF. SDB are characterized by 
sympathetic activation that mediate their adverse effects ultimately leading to high mortality 
rates. Hence, the interest to evaluate MIBG imaging in these patients, in order to clarify the 
prognostic implication of this disorder. 
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1.4 Figure 1. Evaluation of meta-iodobenzylguanidine (I123MIBG) activity in clinical studies. 
Quantification of I123MIBG heart to mediastinum ratio (H/M) and washout rate.  
ROI, region of interest. Modified from Carriò et al. (5). 
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HF is a leading cause of morbidity and mortality worldwide and is characterized by 
sympathetic nervous system hyperactivity that significantly worsens prognosis (1-8). Cardiac 
adrenergic nerve activity has been assessed I123MIBG imaging (9) and, as demonstrated by 
the ADMIRE-HF study (10), the H/M ratio is an independent predictor of HF progression, 
arrhythmic cardiac events and cardiac death. Reduced I123MIBG uptake, likely due to diabetic 
neuropathy, has been also demonstrated in patients with DM without HF and correlated with 
worse prognosis (11,12). DM is common in HF patients with a prevalence range from 10% to 
30% (13), and adversely influences long-term morbidity and mortality of symptomatic and 
asymptomatic HF patients (14,15). In diabetic HF patients enrolled in the ADMIRE-HF trial, 
it has been recently demonstrated that the combination of DM and reduced I123MIBG cardiac 
uptake is an independent predictor of HF progression (16). Yet, the distinct impact of DM on 
cardiac I123MIBG uptake in patients with HF has not been largely investigated, and no 
previous studies have assessed cardiac innervation in matched HF patients with and without 
DM. Therefore, the aim of this study was to evaluate I123MIBG uptake in matched DM and 
non DM patients with severe systolic HF. 
 
Research Design and Methods 
Population and study protocol 
We enrolled 37 consecutive patients with systolic HF and type 2 DM and 38 HF 
patients without DM referring to the Outpatient Clinic for HF at the University of Naples 
Federico II, Italy. To be included in the study, patients needed to fulfill the following criteria: 
LVEF≤40% and dilated cardiomyopathy in at least two consecutive echocardiographic 
evaluations, diagnosis of HF since at least 6 months, stable clinical conditions (NYHA II-III), 
coronary angiography within 1 year from enrollment, no acute coronary syndrome or angina 
in the 6 months before inclusion in the study. Ischemic cardiomyopathy was defined as 
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ventricular dysfunction in myocardial regions subtended by significant (>70% diameter) 
coronary stenosis, with normal regional contractile function at echocardiography and/or 
invasive angiography in regions subtended by coronary arteries without significant stenosis.	  
At the time of enrollment all patients were on optimized medical therapy for HF treatment 
including use of angiotensin-converting enzyme-inhibitors or AT1-antagonists when not 
tolerated, beta-blockers, loop diuretics, anti-aldosterone and digitalis when necessary in 
addition to conventional drugs used for the treatment of cardiovascular risk factors and for 
secondary prevention of coronary heart disease. Fourteen type 2 DM patients with normal 
cardiac function were also included in the study. The diagnosis of DM was confirmed by 
clinical history or through the assessment of at least 2 determinations of fasting plasma 
glucose ≥126 mg/dl or a random plasma glucose test ≥200 mg/dl or with blood glucose levels 
≥200 mg/dl 120 minutes after an oral glucose tolerance test performed with 75 g of glucose 
dissolved in water and confirmed by repeating the test in another day (17). On the same day 
patients underwent clinical examination, venous blood sample collection, transthoracic 
echocardiography and I123MIBG imaging. Demographic data including age, sex, height and 
body weight, body mass index, HF medications, NYHA class, tobacco use, hypertension, 
dyslipidemia, family history of coronary events, duration of DM, presence of comorbidities, 
and ischemic versus non ischemic HF etiology were also collected. A venous blood sample 
was collected in all patients to assess biochemical data, including hemoglobin A1c (HbA1c) 
and NT-proBNP; serum creatinine levels were obtained to estimate glomerular filtration rate 
and assess renal impairment, as previously described (18). Diabetic patients were also 
screened for the presence of diabetic neuropathy using the Michigan Neuropathy Screening 
Instrument (MNSI) examination (19-20). A standard transthoracic echocardiography was 
performed in all patients using a VIVID E9 ultrasound system (GE Healthcare) with second-
harmonic capability and a 3.5 MHz probe. All measurements were performed according to the 
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European Society of Cardiology Recommendations for Chamber Quantification (21). LV 
diameters were obtained in the M-mode view. Global and regional LV function was evaluated 
and LV ejection fraction was calculated from apical four- and two-chamber views using the 
Simpson’s biplane method (21). Wall motion score index was calculated to assess the extent 
of regional wall motion abnormalities. At the end of this initial evaluation, synaptic 
noradrenaline reuptake was assessed by I123MIBG scintigraphy. All patients gave written 
informed consent and local ethic committee approved the protocol. 
I123MIBG Imaging Procedures 
After blockage of the thyroid gland with 300 mg of perchlorate, an activity of 370 
MBq (10 mCi ±10%) I123MIBG (Covidien, Mallinckrodt) was administered over 1 to 2 
minutes and a 10-minute planar anterior chest image was performed at 15 minutes (“early” 
image), and again at 3 hours and 50 minutes (“late” image). Imaging was performed with 
low-energy/high resolution collimators, and the camera peaked at 159 keV with a 
symmetrical 20% energy window. The images were acquired and stored in a 128x128 matrix 
(22). Two observers, blinded about patients’ status (i.e. diabetic or non diabetic), analyzed 
I123MIBG studies (10,23). H/M ratios were calculated from the early and late images after 
drawing regions of interest (7×7 pixels) over the entire heart and upper mediastinum Care was 
taken to exclude lung or liver from the myocardial and large vessels and lung from the 
mediastinum region of interest. I123MIBG WR was calculated using the following formula: 
[(early heart counts/pixel  – early mediastinum counts/pixel) – (late heart counts/pixel decay-
corrected – late mediastinum counts/pixel decay-corrected)]/(early heart counts/pixel – early 
mediastinum counts/pixel). 
Assessment of cardiac autonomic neuropathy 
Evaluation of autonomic neuropathy was performed as previously described (11,24). 
In particular, five tests were used: 1) blood pressure change during standing up and 2) during 
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sustained handgrip; 3) heart rate response to Valsalva maneuver, 4) to standing up and 5) to 
deep breathing. Blood pressure response to standing up was evaluated through the difference 
of systolic blood pressure measured after 2 minutes of lying down and systolic blood pressure 
after standing up, while blood pressure response to 5 minutes of sustained handgrip at 30% of 
maximum voluntary contraction was evaluated through the difference of diastolic blood 
pressure assessed just before release of handgrip and diastolic blood pressure measured before 
starting the maneuver. For heart rate responses, Valsalva maneuver was continued for 15 
minutes at 40 mmHg, then the ratio between the longest RR interval soon after the release and 
the shortest RR during the maneuver was evaluated; heart rate response to standing up was 
assessed as the ratio between the longest RR interval around the 30th beat and the shortest RR 
around the 15th beat (30:15 ratio) and finally heart rate changes to deep breathing was 
calculated through the mean of the differences of maximum and minimum heart rate of three 
consecutive deep breathings (6 breaths/minute). A mean autonomic score was then calculated 
referring to previously described normal, borderline or abnormal values (24) and presence of 
autonomic impairment was defined as an abnormal response to two or more of the five tests 
(11). 
Statistical analysis 
Data are expressed as mean ± standard deviation. The Student t test was used for 
continuous variables. Correlation between variables was assessed by linear regression 
analysis and variables that revealed a statistical significance in univariate model where then 
included in a multivariate analysis. Categorical variables such as NYHA classification were 
analyzed by chi-square test. All data were collected in an Excel database and analyzed by 
SPSS 20.0. Statistical significance was accepted at p ≤0.05. 
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Results 
Patients characteristics 
Mean age of the 75 patients with HF was 67.33±9.6 years (84% male patients) with 
mean LV ejection fraction of 31.03±7.15%. In 52 subjects (69.3%) HF was of ischemic 
etiology and in 23 (30.7%) the etiology was an idiopathic dilated cardiomyopathy. All 
diabetic patients had a diagnosis of type 2 diabetes. No statistically significant differences 
between HF patients with and without DM were found for cardiovascular risk factors, 
demographic variables, comorbidities, LV systolic function, NYHA functional class, serum 
NT-proBNP levels and HF therapy, as shown in Table 1. Medical treatment of DM was as 
follows: 19 patients (51.4%) were on oral antidiabetic agents alone, 2 (5.4%) on insulin alone, 
4 (10.8%) on oral drugs + insulin and 12 subjects (32.4%) were on diet only. Mean HbA1c 
was 6.61±0.69% (49 mmol/mol), 22 patients (59.5%) had a HbA1c measurement ≥6.5%, 
whereas 11 subjects (29.7%) had a HbA1c value >7%. Mean duration of DM was 62±79 
months. 
In 14 patients with DM without HF mean age was 65.9±8.8 years, mean DM duration was 
58±36 months and mean HbA1c was 7.5±1.5 % (58 mmol/mol). 
I123MIBG imaging  
Early and late H/M ratios were significantly lower in patients with HF and DM 
compared to patients with HF without DM. In particular, DM patients showed a mean early 
H/M ratio of 1.65±0.21 vs 1.75±0.21 of non DM subjects (p<0.05) and a mean late H/M ratio 
of 1.46±0.22 vs 1.58±0.24 in non DM subjects (p<0.03). I123MIBG washout rate did not 
significantly differ between the two groups (38±22 vs 34±22%; p=0.44). Both early and late 
H/M were significantly higher in DM patients without HF (2.22±0.35 and 1.99±0.24, 
respectively) when compared to HF patients with (p<0.0001) and without (p<0.0001) DM. 
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Cardiac autonomic neuropathy 
Mean autonomic score was 2.85±0.80 in 20 patients with HF and DM and 3.06±0.62 in 14 
patients with DM without HF (p=ns). Autonomic impairment was found in all but 1 diabetic 
patients with HF and in 12 (86%) diabetic patients without HF. H/M ratios in 12 DM patients 
without HF with autonomic dysfunction were significantly higher compared to 19 DM 
patients with HF and with autonomic dysfunction (early H/M 2.24±0.37 vs 1.62±0.16, 
respectively, p<0.0001; late H/M 1.96±0.24 vs 1.42±0.16, respectively, p<0.0001). In the 
whole group of 34 DM patients evaluated for autonomic impairment, no correlation was 
found between autonomic score and both early and late H/M ratios (r= -0.70, p= 0.723 for 
early H/M; and r= -0.787, p= 0.340 for late H/M). In addition no correlation was found 
between mean autonomic score and HbA1c (r= -0-006, p= 0.977). 
Determinants of I123MIBG uptake in HF patients with and without DM 
In the group of 75 patients with HF, in univariate analysis, early H/M ratio significantly 
correlated with age, LV ejection fraction, NYHA class, HF etiology, NT-proBNP, presence of 
diabetes and HbA1c (Table 2). In multivariate analysis, only HbA1c remained significant 
predictor of early H/M ratio (Table 2).  
In univariate analysis, late H/M ratio significantly correlated with the same variables 
associated with early H/M, and, in addition, with glomerular filtration rate (Table 2). In 
multivariate analysis only etiology of HF remained significantly associated with late H/M. 
Interestingly, when presence of DM was eliminated form the multivariate analysis, HbA1c, in 
addition to HF etiology, resulted significantly correlated with H/M ratio, surely because 
HbA1c acted as a surrogate for DM.  
Determinants of I123MIBG uptake in HF patients with DM 
In the group of HF patients with DM, in univariate analysis, early H/M ratio 
significantly correlated with LV ejection fraction, NT-proBNP and HbA1c (Table 2; Figure 
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1A). In multivariate analysis, LV ejection fraction and HbA1c remained significantly 
associated with H/M (Table 2). Late H/M ratio significantly correlated with age, LV ejection 
fraction, NT-proBNP and HbA1c (Table 2; Figure 1B). In multivariate analysis only HbA1c 
remained significantly associated with late H/M (Table 2). 
Determinants of I123MIBG uptake in HF patients without DM 
In the group of HF patients without DM, in univariate analysis, early H/M ratio 
significantly correlated with age, NYHA class, HF etiology and NT-proBNP, (Table 2; Figure 
1C). In multivariate analysis, none of these parameters remained significant predictor of early 
H/M ratio (Table 2). Late H/M ratio significantly correlated with the same variables 
associated with early H/M, and, in addition, with glomerular filtration rate (Table 2; Figure 
1D). In multivariate analysis only NT-proBNP remained significantly associated with late 
H/M (Table 2). 
 
Discussion 
The present study demonstrates that in DM patients with severe systolic HF, I123MIBG 
cardiac uptake is significantly impaired compared to matched HF patients without DM and to 
DM patients without HF. In addition, in HF patients I123MIBG uptake significantly correlates 
with metabolic control of DM over the last 1 to 2 months, as indicated by the inverse 
association between H/M ratios and HbA1c levels. 
Previous studies 
Impaired I123MIBG cardiac uptake was previously reported in DM patients without 
structural heart disease (12) and in DM patients with silent myocardial ischemia (11). In 
particular, Yufu et al. (12) recently demonstrated, in 108 subjects with type 2 DM but no 
cardiac diseases, that I123MIBG washout rate predicts major adverse cardiac and cerebro-
vascular events.  Moreover, Scholte et al. (25) reported that I123MIBG imaging was able to 
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detect cardiac neuropathy in DM patients before the development of signs of cardiac 
autonomic imbalance, such as heart rate variability, and proposed that I123MIBG imaging may 
provide early prognostic information in these patients. Mechanisms of reduced cardiac 
I123MIBG uptake in DM patients without structural heart diseases are not completely 
understood and presumably different from mechanisms of reduced I123MIBG uptake in HF 
patients with DM. Hyperinsulinemia exerts a sympathoexcitatory effect (26) that may lead to 
enhanced sympathetic tone and reduced I123MIBG uptake in early stages of DM whereas 
cardiac sympathetic denervation, demonstrated at post-mortem studies, would be responsible 
for reduced I123MIBG uptake in long-term diabetic patients with structural heart disease. 
However, few clinical data are available on the impact of DM on cardiac sympathetic activity 
in patients with HF. In fact, the only available data come from a recent retrospective analysis 
of the ADMIRE-HF trial (16). In this analysis, Gerson et al. (16) compared 343 DM patients 
to 618 non DM patients enrolled in the ADMIRE-HF study (10), and reported that HF 
patients with DM and I123MIBG H/M ratio <1.68 had about 3-fold increased risk of HF 
progression compared to HF patients without DM and with H/M ratio <1.68. It was also 
observed that DM patients in the ADMIRE-HF population showed significantly lower 
I123MIBG H/M ratios (either early or late H/M) compared to non DM patients. At variance 
with our study I123 MIBG washout rate was also significantly higher in DM compared to non 
DM patients. However, due to the retrospective design of that analysis, DM and non DM 
patients were not matched for relevant characteristics that may have influenced differences 
observed in I123MIBG parameters. In particular, DM patients had significantly worse clinical 
conditions, significantly less use of beta-blockers and were significantly older than non DM 
patients. Since it has been reported that beta-blocker therapy restores I123MIBG uptake (27) 
and I123MIBG uptake impairment correlates with the degree of clinical deterioration, it is 
	  22	  
difficult to dissect from the data of the ADMIRE-HF trial the distinct influence of DM on 
cardiac I123MIBG uptake in HF patients. 
Apart from the ADMIRE-HF data, no previous studies evaluated the impact of DM on 
cardiac I123MIBG uptake in patients with overt HF, whereas an influence of DM on I123MIBG 
uptake and an association with subclinical HF was previously observed (28,29). In fact, it was 
reported that DM patients with normal LV function at rest who developed contractile 
dysfunction during stress show more impaired I123MIBG uptake compared to patients with 
normal response to stress (28,29). 
A provocative observation of the current study is the inverse correlation between 
HbA1c and either early or late H/M, observed in the whole population and in the subgroup of 
DM patients but not in non DM patients. The strength of this association was supported by 
multivariate analysis that identified HbA1c as the only significant predictor of late H/M ratio 
and as an independent predictor of early H/M ratio in the subgroup of DM patients. To our 
knowledge this observation is novel, and, indeed, no such correlation was found in the 
ADMIRE-HF population (10). However, consistent with our findings, in a previous study 
Ziegler et al. (30) observed in a small series of 12 type-1 DM subjects followed up for 4 
years, that poor glycaemic control, assessed by HbA1c, represents a determinant of cardiac 
I123MIBG uptake impairment that might be prevented by normoglycaemia. In our study 
HbA1c assessment and I123MIBG imaging were obtained in the same day, which may explain 
the lack of correlation observed in the ADMIRE-HF populations. Notably, MIBG uptake in 
diabetic and non diabetic HF patients was significantly lower than that observed in diabetic 
patients with autonomic dysfunction and normal LV function, suggesting that autonomic 
dysfunction does not explain the impairment of MIBG uptake in HF diabetic patients. These 
previous observations and the findings of the current study suggest a potential working 
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hypothesis for future mechanistic studies aimed at assessing whether glycation directly affects 
the process of noradrenaline reuptake at synaptic level. 
 
Limitations 
There are limitations of the study that need to be acknowledged. The first is the 
relatively small number of patients that makes our findings preliminary and warranting further 
confirmation. However, the dispersion of data observed in the present study was of the same 
magnitude of that observed in the larger ADMIRE-HF population (16), as indicated by the 
similar coefficient of variations of H/M ratios in the two studies (data not shown). The small 
number of patients may have prevented differences in the use of beta-blockers and ACE 
inhibitors between DM and non DM patients with HF to reach statistical significance. 
However, both classes of drug demonstrated to improve I123MIBG uptake (31). Thus, the 
higher percent of patients taking beta-blockers and ACE-inhibitor observed in DM patients 
with HF may only have undermined the differences in H/M ratios observed in the current 
study.  In addition, no influence of type of drugs on MIBG uptake was found in univariate 
analysis. In the present study, I123MIBG uptake was evaluated from planar images and, 
therefore, the value of SPECT I123MIBG imaging, reported in previous studies (32), remains 
to be investigated. Likewise, although our findings were not influenced by wall motion score, 
lack of SPECT perfusion rest/stress data does not enable us to exclude an impact of 
myocardial necrosis or myocardial inducible ischemia on our observations.  
 
Conclusion 
In patients affected by chronic severe systolic HF, DM is associated with reduced 
cardiac I123MIBG uptake compared to non DM patients and to DM patients without HF, and 
I123MIBG uptake independently correlates with glycemic control over the last 1 to 2 months. 
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Additional pathophysiological studies are warranted to assess the biological relevance of 
these findings and their potential clinical implications for management of diabetic HF 
patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
	  25	  
References 
1. Rengo G, Lymperopoulos A, Leosco D, Koch WJ. GRK2 as a novel gene therapy target 
in heart failure. J Mol Cell Cardiol. 2011;57:356-365.  
2. Lymperopoulos, A, Rengo G, and Koch WJ. Adrenal adrenoceptors in heart failure: Fine-
tuning cardiac stimulation. Trends Mol Med. 2007;13:503-511. 
3. Rengo G, Perrone Filardi P, Femminella GD, et al. Targeting β-adrenergic receptor 
system via G-protein coupled receptor kinase 2 (GRK2): a new paradigm for therapy and 
prognostic evaluation in heart failure. From bench to bedside. Circulation Heart Failure. 
2012;5:385-391. 
4. Pilotto A, Addante F, Franceschi M, et al. Multidimensional Prognostic Index based on a 
comprehensive geriatric assessment predicts short-term mortality in older patients with 
heart failure. Circ Heart Fail. 2010;3:14-20. 
5. Lymperopoulos A, Rengo G, Zincarelli C, Kim J, Koch WJ. Adrenal beta-arrestin 1 
inhibition in vivo attenuates post-myocardial infarction progression to heart failure and 
adverse remodeling via reduction of circulating aldosterone levels. J Am Coll Cardiol. 
2011;57:356-365. 
6. Lymperopoulos A, Rengo G, Gao E, Ebert SN, Dorn GW 2nd, Koch WJ. Reduction of 
sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure 
progression and improves cardiac function after myocardial infarction. J Biol Chem. 
2010;285:16378-16386. 
7. Lymperopoulos A, Rengo G, Zincarelli C, Soltys S, Koch WJ. Modulation of adrenal 
catecholamine secretion by in vivo gene transfer and manipulation of G protein- coupled 
receptor kinase-2 activity. Mol Ther. 2008;16:302-307. 
	  26	  
8. Rengo G, Zincarelli C, Femminella G, et al. Myocardial β(2) -adrenoceptor gene delivery 
promotes coordinated cardiac adaptive remodelling and angiogenesis in heart failure. Br J 
Pharmacol. 2012;166:2348-2361. 
9. Perrone-Filardi P, Paolillo S, Dellegrottaglie S, et al. Assessment of cardiac sympathetic 
activity by MIBG imaging in patients with heart failure: a clinical appraisal. Heart. 
2011;97:1828-1833.  
10. Jacobson AF, Senior R, Cerqueira MD, et al. Myocardial iodine-123-
metaiodobenzylguanidine imaging and cardiac events in heart failure: results of the 
prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart 
Failure) study. J Am Coll Cardiol. 2010;55:2212-2221. 
11. Langer A, Freeman MR, Josse RG, Armstrong PW. Metaiodobenzylguanidine imaging in 
diabetes mellitus: assessment of cardiac sympathetic denervation and its relation to 
autonomic dysfunction and silent myocardial ischemia. J Am Coll Cardiol. 1995;25:610-
618. 
12. Yufu K, Takahashi N, Okada N, et al. Cardiac iodine-123 metaiodobenzylguanidine (123I-
MIBG) scintigraphy parameter predicts cardiac and cerebrovascular events in type 2 
diabetic patients without structural heart disease. Circ J. 2012;76:399-404. 
13. Soläng L, Malmberg K, Rydén L. Diabetes mellitus and congestive heart failure. Further 
knowledge needed. Eur Heart J. 1999;20:789-795. 
14. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of 
congestive heart failure in Framingham Heart Study subjects. Circulation. 1993;88:107-
115. 
15. Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and 
mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. 
Am J Cardiol. 1996;77:1017-1020. 
	  27	  
16. Gerson MC, Caldwell JH, Ananthasubramaniam K, et al. Influence of diabetes mellitus on 
prognostic utility of imaging of myocardial sympathetic innervation in heart failure 
patients. Circ Cardiovasc Imaging. 2011;4:87-93. 
17. Rydén L, Standl E, Bartnik M, et al. Task Force on Diabetes and Cardiovascular Diseases 
of the European Society of Cardiology (ESC); European Association for the Study of 
Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: 
executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the 
European Society of Cardiology (ESC) and of the European Association for the Study of 
Diabetes (EASD). Eur Heart J. 2007;28:88-136. 
18. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation. National Kidney 
Foundation practice guidelines for chronic kidney disease: evaluation, classification, and 
stratification. Ann Intern Med. 2003;139:137-147. 
19. American Diabetes Association. Standards of medical care in diabetes 2012. Diabetes 
Care. 2012;35 Suppl 1:S11-63. 
20. Moghtaderi A, Bakhshipour A, Rashidi H. Validation of Michigan neuropathy screening 
instrument for diabetic peripheral neuropathy. Clin Neurol Neurosurg. 2006;108:477-481.  
21. Lang RM, Bierig M, Devereux RB, et al. American Society of Echocardiography's 
Nomenclature and Standards Committee; Task Force on Chamber Quantification; 
American College of Cardiology Echocardiography Committee; American Heart 
Association; European Association of Echocardiography, European Society of 
Cardiology. Recommendations for chamber quantification. Eur J Echocardiogr. 
2006;7:79-108. 
22. Pace L, Perrone-Filardi P, Mainenti P, et al. Identification of viable myocardium in 
patients with chronic coronary artery disease using rest-redistribution thallium-201 
tomography: optimal image analysis. J Nucl Med. 1998;39:1869-1874. 
	  28	  
23. Flotats A, Carrió I, Agostini D, et al. EANM Cardiovascular Committee; European 
Council of Nuclear Cardiology. Proposal for standardization of 123I-
metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM 
Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl 
Med Mol Imaging. 2010;37:1802-1812. 
24. Ewing DJ, Martyn CN, Young RJ, et al. The value of cardiovascular autonomic function 
tests: 10 years experience in diabetes. Diabetes Care. 1985;8:491-498. 
25. Scholte AJ, Schuijf JD, Delgado V, et al. Cardiac autonomic neuropathy in patients with 
diabetes and no symptoms of coronary artery disease: comparison of 123I-
metaiodobenzylguanidine myocardial scintigraphy and heart rate variability. Eur J Nucl 
Med Mol Imaging. 2010;37:1698-1705.  
26. Scherrer U, Sartori C. Insulin as a vascular and sympathoexcitatory hormone: implications 
for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. 
Circulation. 1997;96:4104-4113. 
27. Rengo G, Lymperopoulos A, Zincarelli C, et al. β-adrenergic receptor blockade restores 
the GRK2-mediated adrenal α2-adrenergic receptor-catecholamine production axis in 
heart failure. British J Pharmacol. 2012;166:2430-2440 
28. Kreiner G, Wolzt M, Fasching P, et al. Myocardial m-[123]iodobenzylguanidine 
scintigraphy for the assessment of adrenergic cardiac innervation in patients with IDDM: 
comparison with cardiovascular reflex tests and relationship to left ventricular function. 
Diabetes. 1995;44:543-549. 
29. Scognamiglio R, Avogaro A, Casara D, et al. Myocardial dysfunction and adrenergic 
cardiac innervation in patients with insulin-dependent diabetes mellitus. J Am Coll 
Cardiol. 1998;31:404-412. 
	  29	  
30. Ziegler D, Weise F, Langen KJ, et al. Effect of glycaemic control on myocardial 
sympathetic innervation assessed by [123I]metaiodobenzylguanidine scintigraphy: a 4-
year prospective study in IDDM patients. Diabetologia. 1998;41:443-451. 
31. Toyama T, Aihara Y, Iwasaki T, et al. Cardiac sympathetic activity estimated by 123I-
MIBG myocardial imaging in patients with dilated cardiomyopathy after beta-blocker or 
angiotensin-converting enzyme inhibitor therapy. J Nucl Med. 1999;40:217-223. 
32. Boogers MJ, Borleffs CJ, Henneman MM, et al. Cardiac sympathetic denervation 
assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular 
arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol. 
2010;55:2769-2777. 
 
 
 
 
	  30	  
Table 1. Baseline characteristics of HF patients with and without DM. 
Characteristic All Patients with DM Patients without DM p value 
Male sex % (n) 84 (63) 78.4 (29) 89.5 (34) 0.222 
Age (y) 67.33±9.6 68.46±9.89 66.24±9.301 0.319 
LVEF* (%) 31.03±7.15 29.78±6.63 32.24±7.52 0.139 
NYHA† class II-III % (n) 38.7 (29) 58.8 (40) 32.4 (12) 67.6 (25) 44.7 (17) 55.3 (21) 0.154 
Ischemic vs. non-ischemic % 
(n) 
69.3 (52) 73 (27) 65.8 (25) 0.618 
NT-proBNP‡ (ng/L) 1475.08±1169.73 1453.92±1131.36 1495.68±1220 0.878 
HbA1c§ (%) 6.17±0.74 6.61±0.69 5.75±0.49 0.0006 
GFR║ (ml/min/1.73m2) 78.4±32 77.3±34.3 79.5±30.1 0.788 
DM¶ duration (months)  62±79   
Cardiovascular Risk Factors     
Familiar history of CAD# % (n) 32 (24) 37.8 (14) 26.3 (10) 0.329 
Hypertension % (n) 76 (57) 81.8 (30) 71.1 (27) 0.419 
Smokers % (n) 69.3 (52) 64.9 (24) 73.7 (28) 0.460 
Dyslipidemia % (n) 66.7 (50) 73 (27) 60.5 (23) 0.329 
 
Comorbidities 
    
COPD** % (n)     42.7 (32) 43.2 (16) 42.1 (16) 1.000 
Chronic kidney disease % (n) 18.7 (14) 21.6 (8) 15.8 (6) 0.565 
Peripheral artery disease % (n) 10.7 (8) 16.2 (6) 5.3 (2) 0.147 
Atrial fibrillation % (n)    18.7 (14) 10.8 (4) 26.3 (10) 0.137 
Therapy     
ACE inhibitors % (n) 53.3 (40) 59.5 (22) 47.4 (18) 0.357 
AT1 blockers % (n) 24 (18) 18.9 (7) 28.9 (11) 0.419 
β-blockers % (n) 73.3 (55) 81.1 (30) 65.8 (25) 0.192 
- Carvedilol % (n) 53.3 (40) 59.4 (22) 47.3 (18) 1.000 
- Bisoprolol % (n) 20 (15) 21.6 (8) 18.4 (7) 1.000 
Ca++-channel antagonists % (n) 6.7 (5) 8.1 (3) 5.3 (2) 0.674 
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Aldosterone antagonists % (n) 38.7 (29) 35.1 (13) 42.1 (16) 0.637 
Loop diuretics % (n) 69.3 (52) 73 (27) 65.8 (25) 0.618 
Antidiabetic therapy     
Diet % (n)  32.4% (12)   
Oral antidiabetic agents % (n)  51.4% (19)   
Insulin % (n)  5.4% (2)   
Oral agents+Insulin % (n)  10.8% (4)   
Data are expressed as mean±1 standard deviation. Mean follow-up times.  
*LVEF= left ventricular ejection fraction; †NYHA= New York Heart Association; ‡NT-proBNP=  N-terminal pro-brain natriuretic peptide;  
§HbA1c= Hemoglobin A1c; ║GFR= glomerular filtration rate; ¶DM= diabetes mellitus; #CAD= coronary artery disease; **COPD= chronic 
obstructive pulmonary disease  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 2. Determinants of I123MIBG in all patients and in DM and non DM patients. 
	  
	  
	  	   Early H/M*       Late H/M*   
	  	   Univariate analysis 
Multivariate 
analysis  
Univariate 
analysis 
Multivariate 
analysis 
	   All patients 
	  	  
β p β p  β p β p 
 Age -0.337 0.003 -0.184 0.079 
	  
-0.424 0.000 -0.218 0.138 
LVEF† 0.360 0.001 0.092 0.506 
	  
0.398 0.000 0.070 0.619 
NYHA‡ class -0.291 0.011 -0.088 0.399 
	  
-0.362 0.001 -0.184 0.083 
Ischemic vs  
non-Ischemic 
0.281 0.015 0.094 0.365 
	  
0.377 0.001 0.233 0.040 
NT-proBNP§ -0.404 0.000 -0.193 0.158 
	  
-0.462 0.000 -0.235 0.098 
WMSI║ -0.229 0.179 - - 
	  
-0.194 0.256 - - 
GFR¶ 0.198 0.106 - - 
	  
0.331 0.006 0.057 0.699 
Diabetes -0.227 0.050 0.086 0.475 
	  
-0.258 0.025 -0.067 0.580 
HbA1C# -0.473 0.001 -0.444 0.000 
	  
-0.382 0.001 -0.215 0.074 
ACE-Isç 0.128 0.274 - - 
	  
0.124 0.288 - - 
ARBs+ -0.044 0.706 - - 
	  
-0.012 0.915 - - 
BBs^ 0.067 0.568 - - 
	  
0.135 0.247 - - 
 DM° patients 
 β p β p  β p β p 
Age -0.284 0.088 - -  -0.369 0.025 -0.247 0.072 
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LVEF† 0.578 0.000 0.396 0.010  0.446 0.006 0.237 0.195 
NYHA‡ class -0.196 0.245 - -  -0.266 0.112 - - 
Ischemic vs 
Non-Ischemic 
 
0.149 0.379 - -  0.267 0.110 - - 
NT-proBNP§ -0.488 0.002 -0.034 0.818  -0.405 0.013 -0.025 0.890 
WMSI║ -0.334 0.206 - -  -0.336 0.203 - - 
DM° duration -0.054 0.752 - -  0.001 0.995 - - 
MNSI** 0.109 0.521 - -  0.170 0.316 - - 
GFR¶ 0.218 0.224 - -  0.297 0.093 - - 
HbA1C# -0.697 0.000 -0.579 0.000  -0.579 0.000 -0.478 0.001 
ACE-Isç 0.153 0.367 - - 
	  
0.093 0.586 - - 
ARBs+ 0.011 0.950 - - 
	  
0.162 0.337 - - 
BBs^ 0.211 0.210 - - 
	  
0.271 0.104 - - 
Antidiabetic 
therapy 
-0.107 0.528 - - 	   0.028 0.868 - - 
 non DM° patients 
 β p β p  β p β p 
Age -0.359 0.027 -0.180 0.277  -0.452 0.004 -0.252 0.212 
LVEF† 0.125 0.456 - -  0.315 0.054 - - 
NYHA‡ class -0.337 0.038 -0.202 0.217  -0.403 0.012 -0.210 0.161 
Ischemic vs 
Non-Ischemic 
 
0.385 0.017 0.240 0.152  0.454 0.004 0.254 0.104 
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NT-proBNP§ -0.357 0.028 -0.158 0.350  -0.546 0.000 -0.329 0.039 
WMSI║ -0.334 0.206 - -  -0.336 0.203 - - 
GFR¶ 0.173 0.320 - -  0.375 0.026 -0.022 0.916 
HbA1C# -0.075 0.653 - -  0.034 0.841 - - 
ACE-Isç 0.169 0.311 - -  0.222 0.180 - - 
ARBs+ -0.146 0.383 - -  -0.200 0.230 - - 
BBs^ 0.030 0.858 - -  0.130 0.435 - - 
	  
	  
	  
*H/M= Heart to Mediastinum; †LVEF = Left Ventricular Ejection Fraction; ‡NYHA= New York Heart 
Association; §NT-proBNP= N-terminal pro-brain natriuretic peptide;  ║WMSI= Wall Motion Score Index; 
¶GFR= Glomerular Filtration Rate; #HbA1c= Hemoglobin A1c; °DM= diabetes mellitus; **MNSI= 
Michigan Neuropathy Screening Instrument; çACE-Is= Angiotensin Converting Enzyme Inhibitors; 
+ARBs= Angiotensin II Receptor Blockers; ^BBs= Beta-Blockers.
Figure 1. Correlation between HbA1c and early and late H/M ratio in HF patients with and 
without DM. 
 
 
         
1A. Correlation between HbA1c and early H/M ratio in DM patients 
  1B. Correlation between HbA1c and late H/M ratio in DM patients 
1C. Correlation between HbA1c and early H/M ratio in non DM patients 
  1D. Correlation between HbA1c and late H/M ratio in non DM patients 
 
DM= diabetes mellitus; HbA1c= hemoglobin A1c; H/M= heart to mediastinum 
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IR is common in non diabetic patients with HF and has been associated with adverse 
prognosis (1). However, pathogenetic mechanisms that link IR to unfavorable clinical 
outcome in non diabetic HF patients are not completely understood. Hyperinsulinemia, that 
characterizes IR, promotes sympathetic activation (2) and impaired cardiac sympathetic 
innervation has been showed in insulin resistant hypertensive patients with normal LV 
function (3). In addition, reduction of glycated hemoglobin in patients affected by DM with 
normal cardiac function has been correlated with preservation of cardiac sympathetic 
innervation (4). In fact, significantly more impaired cardiac sympathetic innervation has been 
recently reported in diabetic HF patients compared to non diabetic subjects (5) and associated 
with unfavorable clinical outcome (6).  Yet, there are no studies that investigated the status of 
cardiac sympathetic innervation in non diabetic HF patients with IR. 
 Therefore, in the present study we tested the hypothesis that IR is associated with 
more impaired cardiac sympathetic innervation in non diabetic HF patients compared to 
patients with HF but not IR.  
 
Methods 
- Study Population 
One-hundred fifteen consecutive patients (87% males; median age 65±11.3 years) 
with severe-to-moderate systolic HF (mean LVEF 32.5±9.1%) referring to the HF Unit at 
Federico II University of Naples, Italy, were enrolled in the study. To be included in the 
study, patients needed to fulfill the following criteria: LVEF ≤45% in at least two consecutive 
transthoracic echocardiograms, diagnosis of HF since at least 6 months, stable clinical 
conditions (NYHA class I-III), coronary angiography within 1 year from enrollment, no acute 
coronary syndrome or angina in the 6 months before inclusion in the study. At the time of 
enrollment all patients were on optimized medical therapy for HF including angiotensin-
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converting enzyme-inhibitors or AT1-antagonists, beta-blockers, loop diuretics, anti-
aldosterone and digitalis when necessary, in addition to conventional drugs used for treatment 
of cardiovascular risk factors and for secondary prevention of ischemic heart disease. Based 
on IR index, patients were divided into two groups, with and without IR. All patients gave 
written informed consent and local ethic committee approved the protocol. Thirty-eight of 
115 patients belong to the group of non-diabetic HF patients reported in previous study (5). 
- Study Protocol and Procedures 
On the first study day patients underwent clinical examination, venous blood sample 
collection and transthoracic echocardiography. The following day, I123MIBG myocardial 
scintigraphy was performed. At clinical examination, demographic data and medical history 
were recorded. In particular, age, sex, height and body weight, HF medications, tobacco use, 
hypertension, dyslipidemia, family history of coronary events and presence of comorbidities 
were collected. NYHA class was estimated from patients’ symptoms and ischemic versus 
non-ischemic HF etiology was assessed from clinical anamnesis and medical records. 
Venous blood sample collection and assessment of IR 
Venous blood sampling was obtained in all patients to assess biochemical data, 
including fasting glucose and insulin. IR was assessed through the evaluation of Homeostasis 
Model Assessment Insulin Resistance (HOMA-IR). In particular, HOMA-IR was calculated 
using the formula [fasting Glucose (mmol/L) x fasting Insulin (mIU/L)/22.5] and the presence 
of IR was defined as HOMA-IR value >2.5 (7).  
Transthoracic echocardiography 
A standard transthoracic echocardiography was performed in all patients using a 
VIVID E9 ultrasound system (GE Healthcare) with second-harmonic capability and a 3.5 
MHz probe. All measurements were performed according to the European Society of 
Cardiology Recommendations for Chamber Quantification (8). LV diameters were obtained 
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in the M-mode view. Global and regional LV function was evaluated and LVEF was 
calculated from apical four- and two-chamber views using the Simpson’s biplane method.  
I123MIBG imaging procedures 
After blockage of the thyroid gland with 300 mg of perchlorate, an activity of 111 
MBq I123MIBG (Covidien, Mallinckrodt) was intravenously administered over 1 to 2 minutes. 
A 10-minute planar image was acquired from an anterior thoracic view (256 × 256 matrix) 15 
minutes (“early” image) and 3 hours and 50 minutes (“late” image) after tracer administration, 
as previously reported (9). Imaging was performed using a dual-head camera system 
(Skylight, Philips) equipped with low-energy, parallel-hole, high-resolution collimator, and 
peaked at 159 keV with a symmetrical 20% energy window. Two observers, blinded about 
patients’ status, analyzed I123MIBG studies (5,9). MIBG uptake was semi-quantified by 
calculating a H/M ratio after drawing regions of interest (ROI) over the heart and 
mediastinum. This approach provides a highly reproducible index of cardiac sympathetic 
activity (9). Briefly, H/M ratio was computed from the early and late images by dividing the 
mean counts per pixel within the myocardium by the mean counts per pixel within the 
mediastinum. Using dedicated post-processing software on a dedicated workstation (Philips), 
the cardiac ROI was assessed using a manually drawn polygonal ROI placed over the 
myocardium including the LV cavity on the MIBG images. Care was taken to exclude lung or 
liver from the myocardial ROI. The mediastinal ROI with a square shape was placed on the 
upper half of the mediastinum and had a size of 7 × 7 pixels. The location of mediastinal ROI 
was determined using as landmarks the lung apex, the upper cardiac border and the medial 
contours of the lungs. H/M ratio was computed for early and late imaging. By comparing 
early and late activities, the MIBG WR from the myocardium was derived, providing a 
parameter that reflects retention of norepinephrine by sympathetic neurons (9). MIBG WR 
was calculated using the following formula: [(early heart counts/pixel – early mediastinum 
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counts/pixel) – (late heart counts/pixel decay-corrected – late mediastinum counts/pixel 
decay-corrected)]/(early heart counts/pixel – early mediastinum counts/pixel). Reproducibility 
of I123MIBG analysis in our laboratory has been recently reported (10). The absorbed dose per 
unit of activity of I123MIBG was 0.018 mGy/MBq (9). 
- Statistical analysis 
Numerical variables that showed normal distribution were expressed as mean±SD; 
otherwise, variables non-normally distributed were expressed as medians and interquartile 
range. Unpaired t-test or non-parametric Mann-Whitney test were used when appropriate for 
between-group comparison. Categorical variables were analyzed by chi-square test. 
Correlation between variables was assessed by linear regression analysis. Multivariable 
regression analysis was performed in different steps to overcome collinearity between 
covariates included in the model as insulinemia and HOMA-IR. All data were collected in an 
Excel database and analyzed by SPSS 20.0. Statistical significance was accepted at p ≤0.05. 
 
Results 
Of 115 patients, 15 (13%) were in NYHA class I, 66 (57%) in NYHA class II and 34 
(30%) in NYHA class III. In 73 patients (63%) HF was of ischemic origin and in 42 (37%) 
patients etiology of HF was an idiopathic dilated cardiomyopathy. Seventy-six percent of 
patients were on treatment with inhibitors of renin-angiotensin system (ACE inhibitors or 
ARBs) and 72% took beta-blockers (77% on carvedilol, 14% on bisoprolol and 8% other 
beta-blockers), whereas 37% of patients were on mineralcorticoid receptor antagonists. 
Median early H/M ratio was 1.80 (IQR 1.60-1.88) and median value of late H/M ratio was 
1.76 (IQR 1.36-1.70); mean washout rate was 10.08±9.50. 
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- Characteristics of IR and non-IR patients 
Seventy-two (63%) patients showed IR (HOMA-IR >2.5) and 43 (37%) were non-IR 
(HOMA-IR ≤2.5). No significant differences between IR and non-IR patients were observed 
for age, LVEF, NYHA class, HF etiology and HF treatments (Table 1). IR patients showed 
significantly higher fasting insulinemia and fasting glucose levels compared to non-IR 
patients (p<0.001) (Table 1).  
- MIBG uptake in IR and non-IR patients 
IR patients, compared to non-IR patients, showed significantly reduced early H/M 
ratio (1.68 (IQR 1.53-1.85) vs 1.79 (IQR 1.66-1.95); p=0.05) and significantly reduced late 
H/M ratio (1.50 (IQR 1.35-1.69) vs 1.65 (IQR 1.40-1.85); p=0.020) (Figure 1A/B). Washout 
rate did not differ between IR and non-IR patients (10.46±8.79 vs 9.45±10.63; p=0.578). 
- Determinants of I123MIBG uptake 
In the whole population early and late H/M ratio showed a significant inverse 
correlation with age, fasting insulinemia (Figure 2A/B), HOMA-IR (Figure 2C/D) and NYHA 
class and a significant direct correlation with LVEF and HF etiology. These variables were 
included in a multivariable model to assess the independent predictors of I123MIBG uptake. At 
multivariate regression analysis, LVEF (β=0.230; p=0.017), fasting insulinemia (β=-0.223; 
p=0.016) and HOMA-IR (β=-0.264; p=0.004) remained independent predictors of early H/M 
ratio, whereas independent predictors of late H/M ratio were HF etiology (β=0.203; p=0.039) 
and LVEF (β=0.243; p=0.014).   
 
Discussion 
The findings of the present study demonstrate that MIBG uptake is significantly 
reduced in non diabetic HF patients with IR compared to matched non diabetic HF patients 
without IR. Since, reduced MIBG uptake reflects reduced pre-synaptic norepinephrine uptake 
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due to cardiac sympathetic nervous system overactivity, this observation might contribute to 
elucidate the interaction between IR and prognosis in patients with HF (1). 
IR and cardiac sympathetic innervation in HF. The pathogenetic relationship between 
cardiac sympathetic innervation and IR is quite complex, since IR represents, at the same 
time, cause and consequence of HF. In fact, hyperinsulinemia, that characterizes IR, has been 
reported to increase neural sympathetic activation (2), which, in turn, may exert deleterious 
effects on cardiac structure and function, leading to impaired cardiac innervation (11). Very 
consistent with our observations, a previous study by Mongillo et al. (12) reported, in a small 
group of patients, a direct correlation between presynaptic noradrenaline re-uptake, evaluated 
by positron emission tomography using the noradrenaline analogue [11C]meta-hydroxy-
ephedrine, and insulin sensitivity in patients with LV dysfunction. In addition, impaired 
cardiac sympathetic innervation has been reported in type 2 diabetic patients with normal 
cardiac function compared to matched non diabetic patients (13,14), whereas Takahashi et al. 
(15) demonstrated a synergistic detrimental effect of hypertension and type 2 DM on cardiac 
innervation in patients with normal cardiac function, that did not correlate with glycated 
hemoglobin and fasting glucose plasma levels.  
Conversely, IR may be consequence of HF. In fact, it has been demonstrated that 
overstimulation of beta-adrenergic receptors impairs insulin-sensitivity through an Akt-
mediated effect (16). More recently, Ciccarelli et al., using a transgenic mice model, showed 
that ischemia-induced up regulation of G protein-coupled receptor kinase 2 promotes IR by 
interfering with insulin signaling (17). As it has been demonstrated that insulin signaling 
exerts protective effects in the heart through inhibition of apoptosis and oxidative stress (18) 
and enhances cardiomyocyte survival upon ischemic injury (19,20), development of IR may 
set a vicious pathogenetic circle along which IR begets IR through exacerbation of HF. 
Consistent with this hypothesis, it has been recently reported that improvement of loading 
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ventricular conditions, induced by mechanical ventricular assistance, restores insulin 
sensitivity in patients with advanced HF (21). 
Current study provides further novel insights on the association between IR and HF. In 
our study, IR was 63% prevalent in HF patients, quite consistent with the 61% prevalence 
reported by AlZadjali et al. (22) in a population of 129 HF patients. In addition, impaired 
myocardial glucose uptake has been showed in DM patients with coronary artery disease and 
reduced EF (23) as well as in HF patients without DM (24) using positron emission 
tomography. In the current study, patients with HF and IR showed significantly reduced 
MIBG uptake, reflecting sympathetic nervous system overactivity, compared to insulin 
sensitive patients, despite no differences in clinical status, LVEF and HF treatments. The 
finding of impaired values of both early and late H/M ratios strengthens the conception that a 
complex and strict relationship exists between IR and cardiac sympathetic nervous system. 
Conversely, no differences in MIBG WR were found between patients with and without IR. 
This result might depend on the great variability of WR values observed in clinical practice, 
and the limited number of patients enrolled in the current analysis could have been not 
sufficient to demonstrate significant differences. In addition, to further support the interaction 
between IR and adrenergic system, a significant inverse correlation was found between 
HOMA-IR and both early and late H/M, and between fasting insulin plasma levels and early 
and late H/M. Since reduction of H/M ratios are independent prognostic predictors in HF 
patients (6), these data are consistent and further support the adverse prognostic impact of IR 
in patients with HF. The finding of independent role of HF etiology in the prediction of late 
H/M might depend on the higher prevalence of HF of ischemic etiology and related to a more 
clear and defined interaction between ischemia and sympathetic nervous system compared to 
adrenergic impairment observed in idiopathic dilated cardiomyopathy (25). 
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Limitations. Lack of assessment of the effects of therapeutic interventions on IR and 
on MIBG uptake may represent a limitation of the study and deserves further investigation. 
Second, lack of follow up does not allow to establish the independent prognostic value of IR 
in non-DM patients with HF. Finally, the limited number of patients might have 
underestimated differences in WR between groups and studies on larger populations could be 
useful to clarify the value of this parameter in clinical practice. 
Conclusions. Patients with HF and IR demonstrate significantly reduced MIBG uptake 
compared to matched non-IR patients. Thus, the findings contribute to shed light on the 
relationship among IR, HF and cardiac sympathetic nervous innervation. Additional studies 
are needed to elucidate the pathogenetic basis of this complex interaction.  
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Table 1.  Baseline characteristics, glycemic control and I123MIBG Imaging in IR and non-IR 
patients. 
	  
  
 aIR insulin resistance 
 bLVEF left ventricular ejection fraction 
 cNYHA New York Heart Association 
 dHF heart failure 
 eHOMA-IR Homeostasis Model Assessment Insulin Resistance 
 
 
 
 
 
 
 
 IRa  
(n=72, 63%) 
non-IRa  
(n=43, 37%) 
p 
Age (y) 66±10 63±11 0.142 
Male sex (%) 86 88 0.483 
LVEF (%)b 30(25-37) 33(29-37.3) 0.299 
NYHAc  2(2-3) 2(2-2.5) 0.192 
HFd Ischemic etiology (%) 59.7 69.7 0.541 
Ace-inhibitors (%) 50 44.1 0.574 
AT II Receptor Antagonists (%) 25 32.5 0.388 
Beta blockers (%) 73.6 69.7 0.570 
Loop Diuretics (%) 61.1 58.1 0.658 
Aldosterone Antagonists (%) 36.1 39.5 0.756 
Glycemia (mg/dl) 100(91-116)  87(74-98) <0.001  
Insulinemia (mIU/l) 16.6(13-23.5) 5.4(3.5-8.8) <0.001  
HOMA-IRe 4.19(3.19-6.54) 1.24(0.65-1.94) <0.001  
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Figure 1A. Early H/M ratio in IR vs non-IR patients 
	  
 
 
 
I123MIBG: iodine-123 meta-iodobenzylguanidine 
H/M: heart-to-mediastinum 
IR: insulin resistance 
 
 
Figure 1B. Late H/M ratio in IR vs non-IR patients 
 
 
I123MIBG: iodine-123 meta-iodobenzylguanidine 
H/M: heart-to-mediastinum 
IR: insulin resistance 
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Figure 2. Correlation between cardiac sympathetic innervation and fasting insulinemia and 
HOMA-IR. 
 
Panel A: Inverse correlation between insulinemia and Early H/M ratio  
Panel B: Inverse correlation between insulinemia and Late H/M ratio 
Panel C: Inverse correlation between HOMA-IR and Early H/M ratio 
Panel D: Inverse correlation between HOMA-IR and Late H/M ratio 
 
H/M: heart-to-mediastinum 
HOMA-IR: Homeostasis Model Assessment Insulin Resistance 
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3. Sympathetic cardiac innervation and sleep-disordered breathing incrementally 
predict prognosis in patients affected by heart failure with reduced ejection fraction 
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SDB are common in patients with HF, both in form of obstructive sleep apnea (OSA) 
and central sleep apnea (CSA), and have an impact on disease progression and prognosis 
(1,2). Adverse effects of SDB in HF are mainly mediated by increased sympathetic nervous 
system activity that increases myocardial oxygen demand, myocyte necrosis and apoptosis, 
beta-adrenoceptor desensitization and arrhythmogenesis, ultimately leading to high mortality 
rates (3,4). In fact, in patients with OSA, the combination of recurrent apneas, hypoxia and 
arousal is accompanied by an increase in chemoreflex-mediated adrenergic activity that also 
persists during daytime wakefulness (5-7). Similarly, in HF patients with CSA, a further 
increase in resting sympathetic drive has been demonstrated during apnea episodes (8,9) 
leading to adrenergic modulation of chemoreflex and altered ventilatory control (10). 
Increased urinary and blood levels of cathecolamines, higher cardiac noradrenaline spillover 
(11) and impaired muscle sympathetic nerve traffic (4,9) have been demonstrated in HF 
patients affected by SDB and it has been reported that ventilatory therapy reduces 
sympathetic nervous system activity (12,13). However, few data are available on the 
relationship between SDB and impaired cardiac sympathetic innervation, assessed at 
myocardial level, in patients with HF. In the present study we sought to investigate the 
prognostic relationship between SBD and cardiac sympathetic innervation, assessed by 
I123MIBG imaging, in patients affected by systolic HF.  
 
Methods 
Study Population 
Ninety-four consecutive patients (93% male; mean age 66.1±9.8 years) with moderate 
to severe systolic HF (median LVEF 32±7%) referring to the HF Unit at Federico II 
University of Naples, Italy, were included in the present analysis. Study inclusion criteria 
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were: diagnosis of systolic HF (LVEF ≤45%) evaluated by transthoracic echocardiograms in 
at least two consecutive determinations, stable HF since at least 6 months (NYHA I-III), no 
acute coronary syndrome or acute HF in the 6 months before inclusion in the study, ability to 
tolerate nocturnal cardiorespiratory monitoring and capability to sign informed consent and 
take part into the analysis. At enrollment all patients were on optimized medical therapy for 
HF including drugs for prevention of cardiac ischemic events when indicated. The study 
complies with the Declaration of Helsinki, all patients gave written informed consent and 
local ethic committee approved the protocol.  
Study Procedures 
On the first day patients’ medical history and demographic data were collected. In 
particular, information on HF etiology, cardiovascular (CV) risk factors, ongoing therapy, and 
HF symptoms were recorded. A complete clinical examination and transthoracic 
echocardiography were performed and, in the same day, nocturnal cardiorespiratory 
monitoring equipment was applied, as subsequently reported. The day after patients returned 
to remove the device and underwent I123MIBG myocardial scintigraphy. 
Nocturnal cardiorespiratory monitoring 
A Somté (Compumedics, Melbourne, Australia,) software polygraph was used to 
record nocturnal breathing patterns and identify the presence of SDB. Surface electrodes were 
applied to obtain continuous electrocardiogram recording. Airflow was monitored by use of 
thermistors placed at nose and arterial O2 saturation was continuously monitored by a pulse 
oximeter.  Thorax and abdomen movements were registered by pletismographic method. 
Time registration was computer-programmed, starting from patients sleep habits. A sleep 
diary was given to the patient to record the effective hours of sleep and possible awakenings. 
A registration of at least 7 hours was required to analyze the presence of SDB.  
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Nocturnal cardiorespiratory monitoring were analyzed and interpreted by a physician 
skilled in SDB (O.S.). According to the American Academy of Sleep Medicine Criteria (14), 
apnea was defined as a complete cessation of airflow for at least 10 seconds, while hypopnea 
was defined as a decrease in nasal airflow greater than 50% lasting for 10 seconds or more 
and associated to arterial O2 desaturation. Presence and severity of SDB were defined by the 
assessment of Apnea/Hypopnea Index (AHI), defined as the number of respiratory events per 
hour of sleep. AHI value <5 allows to exclude respiratory sleep disorders, whereas AHI 
between 5 and 15 identifies mild disorder, between 16 and 30 a disorder of moderate intensity 
and >30 indicates a severe disturb (14). Based on AHI value patients were divided into two 
groups: SDB (AHI ≥5) and non-SDB (AHI <5). Furthermore, based on the pattern of 
abdominal and thoracic movements and from desaturation patterns, apneic events were 
divided into obstructive and central type. Patients groups’ classification into OSA or CSA was 
determined by the presence of more than 50% of, respectively, obstructive or central apneic 
events. 
Transthoracic echocardiography 
A standard transthoracic echocardiography was performed in all patients using a 
VIVID E9 ultrasound system (GE Healthcare, Little Chalfont, United Kingdom) with second 
harmonic capability and a 3.5 MHz probe. All measurements were performed according to the 
European Society of Cardiology Recommendations for Chamber Quantification (15). LV 
diameters were obtained in the M-mode view. Global and regional LV function was evaluated 
and LVEF was calculated from apical four- and two- chamber views using the Simpson’s 
biplane method. 
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I123MIBG imaging procedures  
After blockage of the thyroid gland with 300 mg of perchlorate, an activity of 111 
MBq I123MIBG (Covidien, Mallinckrodt) was intravenously administered over 1 to 2 minutes. 
A 10-minute planar image was acquired from an anterior thoracic view (256 × 256 matrix) 15 
minutes (“early” image) and 3 hours and 50 minutes (“late” image) after tracer administration, 
as previously reported (16,17). Imaging was performed using a dual-head camera system 
(Skylight, Philips, Amsterdam, The Netherlands) equipped with low-energy, parallel-hole, 
high-resolution collimator, and peaked at 159 keV with a symmetrical 20% energy window. 
Two observers, blinded about patients’ status, analyzed I123MIBG studies (16,18). 123I-MIBG 
uptake was semi-quantified by calculating a heart-to-mediastinum (H/M) ratio after drawing 
regions of interest (ROI) over the heart and mediastinum. This approach provides a highly 
reproducible index of cardiac sympathetic activity (17). Briefly, H/M ratio was computed 
from the early and late images by dividing the mean counts per pixel within the myocardium 
by the mean counts per pixel within the mediastinum. Using dedicated post-processing 
software on a dedicated workstation (Philips), the cardiac ROI was assessed using a manually 
drawn polygonal ROI placed over the myocardium including the LV cavity on the I123MIBG 
images. Care was taken to exclude lung or liver from the myocardial ROI. The mediastinal 
ROI with a square shape was placed on the upper half of the mediastinum and had a size of 
7×7 pixels. The location of mediastinal ROI was determined using as landmarks the lung 
apex, the upper cardiac border and the medial contours of the lungs. H/M ratio was computed 
for early and late imaging. By comparing early and late activities, the I123MIBG WR from the 
myocardium was derived, providing a parameter that reflects retention of norepinephrine by 
sympathetic neurons (16). I123MIBG WR was calculated using the following formula: [(early 
heart counts/pixel – early mediastinum counts/pixel) – (late heart counts/pixel decay-
corrected – late mediastinum counts/pixel decay-corrected)]/(early heart counts/pixel – early 
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mediastinum counts/pixel). Reproducibility of I123MIBG analysis in our laboratory has been 
recently reported (19). The absorbed dose per unit of activity of I123MIBG was 0.018 
mGy/MBq (16). 
Follow-up 
Patients were followed up prospectively. Follow-up was carried out according to 
the local HF program and ended with the last clinical evaluation or with patients’ death. If 
a patient died outside the hospital where he/she was on follow-up, medical records of the 
event and a report of the cause of death were considered. Follow-up analysis was carried 
out until November 2014. The study endpoint was the composite of CV death and 
hospitalization for worsening HF.  
Statistical analysis 
Numerical variables were recorded and analyzed as mean±SD or as medians and 
interquartile range when non-normally distributed. Categorical variables were expressed as 
percentage. Unpaired t-test or non-parametric Mann-Whitney test were used when appropriate 
for between-group comparison. Categorical variables were analyzed by chi-square test. 
Correlation between variables was assessed by linear regression analysis. Potential predictors 
of the study outcome were identified by multiple linear regression analysis, performed in 
different steps to overcome collinearity between covariates included in the model. Survival 
analysis was evaluated through Kaplan Meier curves and compared by Log-Rank test. All 
data were collected in an Excel database and analyzed by SPSS 20.0. Statistical significance 
was accepted at p ≤0.05. 
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Results 
Of 94 patients, 72 (77%) showed SDB and 22 (23%) did not. Median AHI value in the 
whole population was 14±19 and 43 (46%) patients showed a moderate-severe disturb 
(AHI>15).  Among SDB patients, 49 (68%) showed prevalent OSA and 23 (32%) prevalent 
CSA. Mean early H/M ratio was 1.70±0.21 and mean late H/M ratio was 1.53±0.23. In 62 
patients (66%) HF was of ischemic origin and in 32 (34%) etiology of HF was an idiopathic 
dilated cardiomyopathy. Ten patients (11%) were in I NYHA class, 57 (60%) in II NYHA 
class and 27 (29%) patients were in NYHA class III.  
I123MIBG uptake in SBD and non-SDB patients 
No significant differences between SDB and non-SDB patients were observed for age, 
gender, NYHA class, HF etiology, CV risk factors, NT-proBNP and LVEF (Table 1). SDB 
patients showed grater body mass index (BMI) compared to patients without SDB. As per 
protocol, SDB patients showed significantly higher AHI values compared to non-SDB 
patients (p<0.001).  
SDB patients, compared to non-SDB patients, showed significantly reduced early H/M 
(1.67±0.22 vs 1.77±0.13; p=0.019) and late H/M ratio (1.50±0.22 vs 1.61±0.23; p=0.038) 
(Table 1; Figure 1A-B). WR did not differ between groups (Table 1). No significant 
differences were found between OSA (n=49, 53%) and CSA (n=23, 24%) patients for age, 
gender, NYHA class, HF etiology, CV risk factors, NT-proBNP and LVEF (data not shown). 
AHI significantly differed between OSA and CSA patients (18±11 vs 29±15; p=0.001), 
whereas early and late H/M ratios did not significantly differ between groups (early H/M 
1.69±0.24 vs 1.64±0.19, in OSA and CSA respectively, p=ns; late H/M 1.52±0.24 vs 
1.45±0.19, in ODSA and CSA respectively, p=ns). 
At multiple linear regression analysis, in which I123MIBG parameters, age, BMI, 
LVEF and NT-proBNP were included, early and late H/M ratio remained independent 
	  
	  
	  
60	  
predictors of AHI (β=-0.749; p<0.001; β=-0.830; p=0.001, respectively). Similarly, AHI was 
the only predictor of early H/M (β=-0.643; p<0.001) and of late H/M (β=-0.453; p<0.002). 
 
Prognostic impact of SDB and I123MIBG parameters 
Patients were followed up for a mean of 29±18 months (range 6-43 months), and all of 
them completed at least 6 months of follow-up. In the whole population, 4 (4.2%) patients 
experienced CV death, while 17 (18%) were hospitalized for worsening HF. Analyzing event 
rate distribution and survival rates, median AHI value, SDB severity and late H/M showed the 
best discriminatory power identifying worse prognosis.  
Dividing patients into two groups above and below the median AHI (median 
AHI=14), patients with AHI above the median (n=49) showed significantly higher event rates 
compared to patients with AHI below the median (n=45) (35% vs 9%, respectively; p=0.003). 
Kaplan-Meier analysis showed significantly worse prognosis in patients with AHI above the 
median for the composite outcome of CV death and HF hospitalization (Log-Rank=<0.001; 
Figure 2A).  
When patients were divided into two groups according to SDB severity, patients with 
a moderate-severe disturb (AHI >15; n=43) showed significantly higher event rates compared 
to patients with mild or no disorder (AHI ≤15; n=51) (35% vs 11.7%; p=0.007). Kaplan-
Meier analysis showed significantly worse survival in patients with moderate-severe disorder 
for the composite outcome of CV death and HF hospitalization (Log-Rank=0.001; Figure 2B).  
In addition, event rates of the combined endpoint significantly differed in patients with 
normal (≥1.60) (20) or abnormal late H/M ratio (<1.60). Patients with late H/M ratio ≥1.60 
(n=36) showed significantly lower event rates compared to patients with late H/M <1.60 
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(n=58) (11% vs 29%; p=0.039). Kaplan-Meier analysis showed significantly worse survival 
in patients with impaired cardiac sympathetic innervation (Log-Rank=0.042; Figure 2C). 
Incremental prognostic impact of SDB and I123MIBG parameters 
An additional analysis was performed to assess the incremental prognostic value of 
H/M and SBD. 
Addition of median AHI subgroups (<14 vs ≥14) to the binary late H/M classification 
(<1.60 vs ≥1.60) identified four new groups of patients (1:late H/M ≥1.60 and AHI <14; 2:late 
H/M ≥1.60 and AHI ≥14; 3:late H/M <1.60 and AHI <14; 4:late H/M <1.60 and AHI ≥14) 
and significant differences in event rates occurrence were observed among groups (5% vs 
19% vs 12% vs 42%, respectively; p= 0.005). At Kaplan-Meier analysis the integration of 
these variables provided further stratification for the combined endpoint of CV death and HF 
hospitalizations (Log-Rank<0.001; Figure 3A). The worst prognosis was observed in patients 
with AHI above the median and late H/M ratio <1.60.  
Similarly, highly significant differences in prognosis were found adding patients’ 
stratification for SDB severity (mild or no SDB vs moderate-severe disorder) to the binary 
H/M result (<1.60 vs. ≥1.60). Event rates were significantly different among the new four 
groups (1:late H/M ≥1.60 and mild or no SDB; 2:late H/M ≥1.60 and moderate-severe SDB; 
3:late H/M <1.60 and mild or no SDB; 4:late H/M <1.60 and moderate-severe SDB - event 
rates: 5% vs 19% vs 12% vs 44%, respectively; p= 0.008) and significant survival differences 
were found at Kaplan-Meier analysis (Log-Rank=0.001; Figure 3B), with the worst prognosis 
observed in patients with moderate-severe disorder and late H/M ratio <1.60. 
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Discussion 
The findings of the present study demonstrate that SDB are highly prevalent (77%) in 
patients with chronic systolic HF and associated with more impaired cardiac sympathetic 
innervation. SBD and cardiac sympathetic innervation parameters incrementally predict the 
composite endpoint of CV survival and HF hospitalization, identifying a subgroup of patients 
with abnormal H/M ratio and moderate to severe SBD who show the worst prognosis. 
In the present study significant lower values of early and late H/M ratios, indicating 
impaired cardiac sympathetic innervation due to chronically increased sympathetic drive, 
were observed in patients with HF and SDB, compared to patients without SDB, despite 
comparable LVEF and functional HF class. Notably, I123MIBG parameters were the only 
independent predictors of SBD and, inversely, AHI was the best descriptor of cardiac 
adrenergic innervation status. Thus, these findings point to an independent contribution of 
SDB to sympathetic stimulation in patients with HF, leading to more pronounced beta-
receptor desensitization and, hence, reduced H/M ratios measured at cardiac level. 
In our study, early and late H/M ratio did not differ between patients with OSA 
compared to patients with CSA. This finding may appear not consistent with previous studies 
that investigated the impact of SDB in patients with HF on sympathetic activation using 
different approaches. In fact, Solin et al. (3) reported that overnight urinary norepinephrine 
levels were significantly increased in 90 HF patients compared to healthy subjects and to 
patients with OSA not affected by HF. Among HF patients, those with CSA revealed more 
increased norepinephrine levels compared to patients with HF and no SDB or with HF and 
OSA. However, patients with CSA had significantly reduced LVEF and significantly more 
compromised hemodynamic status compared to patients with HF and OSA. Similarly, in a 
study of 55 patients with severe systolic HF, Mansfield et al. (11) reported that total body and 
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cardiac norepinephrine spillover were more increased in patients with CSA compared to 
patients with OSA or without SDB, but also in this study these differences were attributed to 
the more impaired hemodynamic status of patients with CSA compared to patients with OSA. 
Yet, catecholamine levels do not strictly mirror the status of cardiac innervation as depicted 
from innervation imaging (20) and only few studies have used MIBG imaging to assess the 
impact of SDB on cardiac innervation in patients with HF. Nanjo et al. (21) reported in a 
study of 53 patients with stable chronic dilated cardiomyopathy, that late H/M ratio was 
significantly lower in HF patients with SDB compared to patients without SDB. However, in 
this study no nocturnal cardiorespiratory monitoring or complete polysomnography were 
performed and the presence of SDB was assessed using 24-h pulse oximetry. In a study of 59 
HF patients, Tamura et al. (22) found that late H/M ratio was significantly lower and WR 
significantly higher in patients with HF and CSA compared to patients with HF and OSA. 
However, significantly higher BNP levels in patients with CSA indicated that hemodynamic 
status was more compromised in patients with CSA, potentially explaining their observation. 
Thus, to our knowledge, this is the first study that compared the status of cardiac sympathetic 
innervation of patients with HF and OSA or CSA, with similar degree of functional and 
hemodynamic LV impairment. 
Prognostic impact of SDB in relation to I123MIBG findings  
Patients with AHI above the median showed significantly increased incidence of the 
combined endpoint of cardiac death or re-hospitalization for worsening HF compared to 
patients with AHI below the median. In addition, dividing patients according to SDB severity, 
significantly higher incidence of the combined endpoint was found in patients with moderate-
severe disorder compared to patients with only mild or absent disorder, using an AHI 
threshold >15 to identify patients with moderate-severe SDB, as previously suggested (14). 
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Our findings appear very consistent with those reported by Wang et al. (23) in 164 
patients with HF divided between patients without SDB or only mild OSA, identified by AHI 
≤15, and patients with untreated OSA identified by AHI >15. In that study, that excluded 
patients with CSA, an independent impact of OSA was found on mortality rate. However, no 
parameters of cardiac sympathetic status were reported. Taken together, these findings 
suggest that HF patients also affected by SDB develop more impaired cardiac sympathetic 
innervation, as a result of more increased chronic sympathetic drive, leading to more adverse 
prognosis. Consistent with our study, Lanfranchi et al. (24) reported that the presence of 
impaired respiration during sleep was associated with increased mortality rate in 62 patients 
with systolic HF, and that an AHI ≥30 was an independent predictor of prognosis. Bakker et 
al. (25) also reported, over a 10-year follow-up of 53 HF patients, a significant decreased 
survival in patients with CSA compared to those with OSA or those without SDB.  
However, in these studies, at variance with the current analysis, SDB was analyzed as 
a single prognostic parameter and not integrated in a model that accounts for other prognostic 
parameters, including I123MIBG findings, to assess its incremental prognostic value. In fact, 
the ADMIRE-HF trial (20) reported that a value of late H/M <1.60 identifies patients at 
increased risk of cardiac death, arrhythmic events, HF progression and all-cause mortality 
with incremental prognostic value to natriuretic peptide levels and LVEF. Consistent with that 
study, our findings demonstrate an increased risk of CV death and HF hospitalizations in HF 
patients with late H/M value <1.60 compared to patients with late H/M ≥1.60. Inclusion in the 
model of both AHI and late H/M further stratified clinical outcome. In fact, when median 
AHI was combined with late H/M ratio, four groups of patients were identified with 
significant event rates differences, with the highest event rate observed in patients with late 
H/M <1.60 and AHI above the median value (Figure 3A). Similarly, adding SDB severity 
classification to late H/M, significant event rates and survival differences were found among 
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the new four classes of patients with the worst event rate in subjects with late H/M <1.60 and 
SDB of moderate-severe grade (Figure 3B).  
Limitations 
This study did not assess the effects of intervention for SBD on cardiac sympathetic 
innervation. This prevents to verify whether changes of cardiac innervation status are 
associated with clinical outcome and can represent a meaningful surrogate prognostic 
endpoint in HF patients. In fact, a recent study reported that short-term continuous positive 
airway pressure was associated with a significant improvement of pre-synaptic catecholamine 
retention, indicating improved cardiac innervation status, in patients with HF and OSA (13). 
However, no prognostic data were reported. Collectively, these findings generate the 
hypothesis to be tested that therapeutic-induced changes of cardiac innervation parameters 
may represent a short-term marker of subsequent clinical outcome in HF patients with SBD. 
However, this study is the first investigating the association among SDB, cardiac innervation 
and prognosis, reporting the largest population of HF patients with SDB undergoing 
I123MIBG imaging. 
Conclusions 
Patients with systolic HF and SDB show a greater impairment of cardiac adrenergic 
innervation and more adverse prognosis compared to HF patients without SDB. Further 
studies are warranted to assess whether SDB therapy, through reversal of sympathetic 
innervation abnormalities, improves prognosis in HF patients with SDB. 
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Table 1. Characteristics and I123MIBG uptake in the two groups of patients with SDB and no-
SDB. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*SDB sleep disordered breathing 
†BMI body mass index 
‡LVEF left ventricular ejection fraction 
§NYHA New York Heart Association 
 ||H/M heart to mediastinum ratio 
 
  
 *SDB 
(n=72) 
no-SDB 
(n=22) 
p  
Age (y) 66.9±9.7 63.2±9.8 ns 
Male sex (%) 92 95 ns 
BMI† 29.0±4.1 26.4±3.7 0.01 
LVEF‡ (%, IQR) 32(8) 33(9) ns 
NYHA§ 2.1±0.7 2.3±0.6 ns 
NT-proBNP (pg/ml, IQR) 441(1720) 182(149) ns 
Ischemic Etiology (%) 62 77 ns 
Hypertension (%) 82 73 ns 
Diabetes (%) 36 32 ns 
Dyslipidemia (%) 68 77 ns 
Cigarette Smoking (%) 53 64 ns 
Early H/M|| 1.67±0.22 1.77±0.13 0.019 
Late H/M|| 1.50±0.22 1.61±0.23 0.038 
Washout rate (%, IQR) 10.1(10) 8.4(9.4) ns 
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Figure 1A. Early H/M in the two groups of patients with and without SDB  
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Figure 1B. Late H/M in the two groups of patients with and without SDB 
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Figure 2. Kaplan-Meier analysis for the composite endpoint of cardiovascular death and 
hospitalization for worsening HF 
Panel A. Kaplan-Meier analysis for the composite endpoint of cardiovascular death and 
hospitalization for worsening HF in patients above median AHI (green curve) and below 
median AHI (blue curve). 
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Figure 2. Kaplan-Meier analysis for the composite endpoint of cardiovascular death and 
hospitalization for worsening HF 
Panel B. Kaplan-Meier analysis for the composite endpoint of cardiovascular death and 
hospitalization for worsening HF in patients with mild or no SDB (blue curve) and with 
moderate-severe SDB (green curve). 
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Figure 2. Kaplan-Meier analysis for the composite endpoint of cardiovascular death and 
hospitalization for worsening HF 
Panel C. Kaplan-Meier analysis for the composite endpoint of cardiovascular death and 
hospitalization for worsening HF in patients with late H/M <1.60 (blue curve) and late H/M 
≥1.60 (green curve). 
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Figure 3. Kaplan-Meier analysis for the composite endpoint of cardiovascular death and 
hospitalization for worsening HF showing incremental value of late H/M to median AHI and 
SDB severity. 
Panel A. Addition of binary late H/M division (<1.60 vs. ≥1.60) further stratifies patients 
already divided in the two groups above and below median AHI (14). 
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Figure 3. Kaplan-Meier analysis for the composite endpoint of cardiovascular death and 
hospitalization for worsening HF showing incremental value of late H/M to median AHI and 
SDB severity. 
Panel B. Addition of binary late H/M division (<1.60 vs. ≥1.60) further stratifies patients 
already divided in the two groups of mild/no-SDB and moderate-severe SDB. 
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5. Closing remarks 
Morbidity and mortality related to HF-REF show an exponential growth due to 
population aging and prolonged life expectancy. Numerous factors have been already 
identified as prognostic indicators in patients affected by HF, however several pathogenetic 
mechanisms remain still unclear and continue to adversely affect patients’ prognosis and 
disease progression.  
Sympathetic nervous system hyperactivation play a detrimental role in the 
advancement of cardiac dysfunction and it is strictly related to several metabolic mechanisms 
that additionally influence prognosis. The identification of the pathophysiological pathway 
that relates adrenergic impairment with metabolic disorders might help in the identification of 
new therapeutic targets to improve HF survival and quality of life.  
Assessment of cardiac sympathetic activity by I123MIBG imaging represents an 
interesting and promising tool to assess adrenergic imbalance in HF and to follow its 
deleterious effects on disease progression. However, the lack of wide prospective outcome 
data currently remains a limitation for routine clinical use. Prospective clinical studies are 
needed, aimed at assessing whether I123MIBG imaging will ultimately have an impact on the 
management of HF in clinical practice. 
 
 
 
 
 
 
 
 
